A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations

期刊论文
发表日期：

2024年11月5日

查看全文

Guillermo Suay,
Paloma Martín-Martorell,
Francisco Aparisi,
María Arnal,
María Guirado,
Aitor Azkárate,
Javier Garde-Noguera,
José David Cumplido-Burón,
Amelia Insa,
José Francisco González-Muñoz,
Sarai Palanca,
María Díaz,
Alfredo Sánchez-Hernández,
Óscar Juan-Vidal

摘要

Objectives

EGFR exon 20 insertion (EGFRex20ins) mutations are found in up to 4% of all patients with non-small cell lung cancer (NSCLC). These patients are often insensitive to EGFR-tyrosine kinase inhibitors (TKIs) and have worse prognosis than patients with more common EGFR mutations. In this multicenter, retrospective, real-world study, we sought to determine whether the administration of recently approved treatments that specifically target EGFRex20ins mutations could significantly improve outcomes in this patient population.

Materials and methods

We evaluated the clinical features of 41 patients diagnosed with NSCLC and EGFRex20ins mutations, their evolution, and response to treatments received across 7 hospitals in the Valencian Community, Spain, between 31st December 2012 and 31st December 2022.

Results

32 patients (72%) developed metastatic disease, and 29 (71%) of them received oncological treatment. We found that administering a targeted therapy against EGFRex20ins mutations (amivantamab, mobocertinib and/or sunvozertinib) at some point during the course of treatment, significantly increased the median OS of metastatic patients from 8 months (95% CI 0–21.7) to 30 months (95% CI 11.1–48.8; Hazard ratio = 0.297, p = 0.02).

Conclusion

Our findings contribute to the evolving standard of care for this specific population and highlight the clinical benefits of targeted cancer therapies.